LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain. | MicrobiomeTrials← Back to trialsNCT07202897
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-01-07Est. Completion: 2032-01-07
Enrollment target: 532 participants Locations- CHU Angers, Angers, France
- CHU Bordeaux Haut-Levêque, Bordeaux, France
- CHU Brest - Hôpital La Cavale Blanche, Brest, France
- CHU Caen, Caen, France
- CHU Dijon - Hôpital François Mitterrand, Dijon, France
- CHU Grenoble Alpes, Grenoble, France
- CHU Lille, Lille, France
- APHM - Hôpital La Timone, Marseille, France
- CHU de Nantes -Hôpital Nord Laennec, Nantes, France
- AP-HP Höpital la Pitié-Salpétrière, Paris, France
- APHP Hopital Européen Georges Pompidou, Paris, France
- APHP, Hôpital Lariboisière, Paris, France
- CHU Rennes - Hôpital Pontchaillou, Rennes, France
- CHU de Rouen, Rouen, France
- CHU Rangueil Toulouse, Toulouse, France
- CHU de TOURS - HOPITAL TROUSSEAU, Tours, France
- CHU Nancy, Vandœuvre-lès-Nancy, France
Other microbiome trials you might be interested in
Amyloidosis, HereditaryAmyloidosis CardiacAmyloidosis, FamilialTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyTransthyretin Gene Mutation
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substit…
New York, United StatesEst. completion Jun 30, 2027
Acute Pain
This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The st…
Bethesda, United StatesEst. completion Dec 31, 2029
Obstructive Hypertrophic Cardiomyopathy
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a p…
Anchorage, United StatesEst. completion Aug 17, 2029